{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">Rosuvastatin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">acenocoumarol</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rosuvastatin   increases   the anticoagulant effect of   acenocoumarol .  Manufacturer advises monitor INR and adjust dose .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acipimox\" outputclass=\"int-drug\">Acipimox</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of rhabdomyolysis when given with</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acipimox   is predicted to   increase   the risk of rhabdomyolysis when given with   rosuvastatin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acipimox</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"alcohol\" outputclass=\"int-drug\">alcohol</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  alcohol  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alcohol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"alectinib\" outputclass=\"int-drug\">alectinib</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  alectinib  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alectinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"antacids\" outputclass=\"int-drug\">antacids</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   antacids   decrease   the absorption of   oral   rosuvastatin .  Manufacturer advises separate administration by 2 hours .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Antacids</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">Apalutamide</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Apalutamide   slightly   decreases   the exposure to   rosuvastatin .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"asparaginase\" outputclass=\"int-drug\">asparaginase</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  asparaginase  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asparaginase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises avoid or adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"bedaquiline\" outputclass=\"int-drug\">bedaquiline</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  bedaquiline  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bedaquiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bezafibrate\" outputclass=\"int-drug\">Bezafibrate</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of rhabdomyolysis when given with</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bezafibrate   increases   the risk of rhabdomyolysis when given with   rosuvastatin .  Manufacturer advises adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bezafibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">Cabazitaxel</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises take 12 hours before or 3 hours after <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/cabazitaxel.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5557\">cabazitaxel</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cabazitaxel   is predicted to   affect   the exposure to   rosuvastatin .  Manufacturer advises take 12 hours before or 3 hours after  cabazitaxel .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabazitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">carbamazepine</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  carbamazepine  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ceftobiprole\" outputclass=\"int-drug\">Ceftobiprole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ceftobiprole   is predicted to   increase   the concentration of   rosuvastatin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftobiprole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">Ciclosporin</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ciclosporin   markedly   increases   the exposure to   rosuvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ciprofibrate\" outputclass=\"int-drug\">Ciprofibrate</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of rhabdomyolysis when given with</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ciprofibrate   increases   the risk of rhabdomyolysis when given with   rosuvastatin .  Manufacturer advises adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciprofibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"clavulanate\" outputclass=\"int-drug\">clavulanate</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  clavulanate  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clavulanate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">Clopidogrel</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Clopidogrel   increases   the exposure to   rosuvastatin .  Manufacturer advises adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"colchicine\" outputclass=\"int-drug\">Colchicine</ph> <ph outputclass=\"int-effectQualifier\">has been reported to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">rhabdomyolysis when given with</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution or monitor</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Colchicine   has been reported to   cause   rhabdomyolysis when given with   rosuvastatin .  Manufacturer advises caution or monitor .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Colchicine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"crisantaspase\" outputclass=\"int-drug\">crisantaspase</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  crisantaspase  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crisantaspase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"dactinomycin\" outputclass=\"int-drug\">dactinomycin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  dactinomycin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dactinomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"dantrolene\" outputclass=\"int-drug\">dantrolene</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  dantrolene  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dantrolene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">Rosuvastatin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of rhabdomyolysis when given with</ph> <ph otherprops=\"daptomycin\" outputclass=\"int-drug\">daptomycin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rosuvastatin   is predicted to   increase   the risk of rhabdomyolysis when given with   daptomycin .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daptomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"darolutamide\" outputclass=\"int-drug\">Darolutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Darolutamide   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darolutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"demeclocycline\" outputclass=\"int-drug\">demeclocycline</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  demeclocycline  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Demeclocycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"doxycycline\" outputclass=\"int-drug\">doxycycline</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  doxycycline  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxycycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   slightly   increases   the exposure to   rosuvastatin .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elbasvir\" outputclass=\"int-drug\">Elbasvir</ph> <ph outputclass=\"int-substanceQualifier\">with grazoprevir</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elbasvir   with grazoprevir   moderately   increases   the exposure to   rosuvastatin .  Manufacturer advises adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Elbasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"elexacaftor\" outputclass=\"int-drug\">Elexacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Elexacaftor   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Elexacaftor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eltrombopag</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   decreases   the exposure to   rosuvastatin .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eslicarbazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fenofibrate\" outputclass=\"int-drug\">Fenofibrate</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of rhabdomyolysis when given with</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"fenofibrate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/fenofibrate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1686\">fenofibrate</xref></ph> and <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> doses</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fenofibrate   increases   the risk of rhabdomyolysis when given with   rosuvastatin .  Manufacturer advises adjust  fenofibrate  and  rosuvastatin  doses .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenofibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"filgotinib\" outputclass=\"int-drug\">Filgotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Filgotinib   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Filgotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"flucloxacillin\" outputclass=\"int-drug\">flucloxacillin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  flucloxacillin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flucloxacillin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">fluconazole</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  fluconazole  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012490",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012490_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fostamatinib\" outputclass=\"int-drug\">Fostamatinib</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises consider alternatives</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fostamatinib   slightly   increases   the exposure to   rosuvastatin .  Manufacturer advises consider alternatives .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fostamatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012491",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012491_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fostemsavir\" outputclass=\"int-drug\">Fostemsavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust starting dose and monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fostemsavir   increases   the exposure to   rosuvastatin .  Manufacturer advises adjust starting dose and monitor .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fostemsavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012492",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012492_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fusidate\" outputclass=\"int-drug\">Fusidate</ph> <ph outputclass=\"int-effectQualifier\">has been reported to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">rhabdomyolysis when given with</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fusidate   has been reported to   cause   rhabdomyolysis when given with   rosuvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fusidate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012493",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012493_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"gemfibrozil\" outputclass=\"int-drug\">Gemfibrozil</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of rhabdomyolysis when given with</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Gemfibrozil   increases   the risk of rhabdomyolysis when given with   rosuvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemfibrozil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012494",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012494_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"glecaprevir\" outputclass=\"int-drug\">Glecaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with pibrentasvir</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Glecaprevir   with pibrentasvir   moderately   increases   the exposure to   rosuvastatin .  Manufacturer advises use with caution and adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glecaprevir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012495",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012495_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"grazoprevir\" outputclass=\"int-drug\">Grazoprevir</ph> <ph outputclass=\"int-substanceQualifier\">with elbasvir</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Grazoprevir   with elbasvir   moderately   increases   the exposure to   rosuvastatin .  Manufacturer advises adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Grazoprevir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012496",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012496_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"isavuconazole\" outputclass=\"int-drug\">Isavuconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Isavuconazole   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isavuconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012497",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012497_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"isoniazid\" outputclass=\"int-drug\">isoniazid</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  isoniazid  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoniazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012498",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012498_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">itraconazole</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  itraconazole  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012499",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012499_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ledipasvir\" outputclass=\"int-drug\">Ledipasvir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ledipasvir   with sofosbuvir   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ledipasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012500",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012500_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">leflunomide</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  leflunomide  can increase the risk of hepatotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012500_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">Leflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Leflunomide   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012501",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012501_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"lenalidomide\" outputclass=\"int-drug\">lenalidomide</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  lenalidomide  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012502",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012502_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"letermovir\" outputclass=\"int-drug\">Letermovir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Letermovir   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Letermovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012503",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012503_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"lomitapide\" outputclass=\"int-drug\">lomitapide</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  lomitapide  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomitapide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012504",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012504_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises avoid or adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012505",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012505_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"lymecycline\" outputclass=\"int-drug\">lymecycline</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  lymecycline  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lymecycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012506",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012506_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"mercaptopurine\" outputclass=\"int-drug\">mercaptopurine</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  mercaptopurine  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mercaptopurine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012507",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012507_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  methotrexate  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012508",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012508_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"micafungin\" outputclass=\"int-drug\">micafungin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  micafungin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Micafungin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012509",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012509_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"minocycline\" outputclass=\"int-drug\">minocycline</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  minocycline  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Minocycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012510",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012510_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"neratinib\" outputclass=\"int-drug\">neratinib</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  neratinib  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Neratinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012511",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012511_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">Nicotinic acid</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of rhabdomyolysis when given with</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicotinic acid   might   increase   the risk of rhabdomyolysis when given with   rosuvastatin .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012512",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012512_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"olaparib\" outputclass=\"int-drug\">Olaparib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Olaparib   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012513",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012513_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"osimertinib\" outputclass=\"int-drug\">Osimertinib</ph> <ph outputclass=\"int-effect\">causes a small increase in</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Osimertinib   causes a small increase in   the exposure to   rosuvastatin .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osimertinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012514",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012514_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"oxytetracycline\" outputclass=\"int-drug\">oxytetracycline</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  oxytetracycline  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxytetracycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012515",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012515_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"paracetamol\" outputclass=\"int-drug\">paracetamol</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  paracetamol  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paracetamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012516",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012516_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">Pazopanib</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Pazopanib   might   affect   the exposure to   rosuvastatin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"pegaspargase\" outputclass=\"int-drug\">pegaspargase</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  pegaspargase  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pegaspargase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">Rosuvastatin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"phenindione\" outputclass=\"int-drug\">phenindione</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rosuvastatin   is predicted to   increase   the anticoagulant effect of   phenindione .  Manufacturer advises monitor INR and adjust dose .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"pibrentasvir\" outputclass=\"int-drug\">Pibrentasvir</ph> <ph outputclass=\"int-substanceQualifier\">with glecaprevir</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Pibrentasvir   with glecaprevir   moderately   increases   the exposure to   rosuvastatin .  Manufacturer advises use with caution and adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pibrentasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">Regorafenib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Regorafenib   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">Ribociclib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor for toxicity</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ribociclib   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises monitor for toxicity .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"roxadustat\" outputclass=\"int-drug\">Roxadustat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Roxadustat   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises monitor adverse effects and adjust dose .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Roxadustat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"sotorasib\" outputclass=\"int-drug\">sotorasib</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  sotorasib  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotorasib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"streptozocin\" outputclass=\"int-drug\">streptozocin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  streptozocin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptozocin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"sulfasalazine\" outputclass=\"int-drug\">sulfasalazine</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  sulfasalazine  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfasalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tedizolid\" outputclass=\"int-drug\">Tedizolid</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tedizolid   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tedizolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tepotinib\" outputclass=\"int-drug\">Tepotinib</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tepotinib   might   increase   the exposure to   rosuvastatin .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tepotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"teriflunomide\" outputclass=\"int-drug\">teriflunomide</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  teriflunomide  can increase the risk of hepatotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012529_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"teriflunomide\" outputclass=\"int-drug\">Teriflunomide</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Teriflunomide   moderately   increases   the exposure to   rosuvastatin .  Manufacturer advises adjust  rosuvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Teriflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"tetracycline\" outputclass=\"int-drug\">tetracycline</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  tetracycline  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetracycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"tigecycline\" outputclass=\"int-drug\">tigecycline</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  tigecycline  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tigecycline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012532",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012532_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012533",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012533_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tivozanib\" outputclass=\"int-drug\">Tivozanib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tivozanib   is predicted to   decrease   the exposure to   rosuvastatin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tivozanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"trabectedin\" outputclass=\"int-drug\">trabectedin</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  trabectedin  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trabectedin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"valproate\" outputclass=\"int-drug\">valproate</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  valproate  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valproate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012536",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012536_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"velpatasvir\" outputclass=\"int-drug\">Velpatasvir</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rosuvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1645\">rosuvastatin</xref></ph> dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Velpatasvir   moderately   increases   the exposure to   rosuvastatin .  Manufacturer advises adjust  rosuvastatin  dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Velpatasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012537",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012537_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"venetoclax\" outputclass=\"int-drug\">Venetoclax</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Venetoclax   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venetoclax</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012538",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012538_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of hepatotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  rosuvastatin  and  vincristine  can increase the risk of hepatotoxicity. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012539",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012539_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voxilaprevir\" outputclass=\"int-drug\">Voxilaprevir</ph> <ph outputclass=\"int-substanceQualifier\">with sofosbuvir and velpatasvir</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voxilaprevir   with sofosbuvir and velpatasvir   markedly   increases   the exposure to   rosuvastatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voxilaprevir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012540",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2#bnf_i1643858012540_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rosuvastatin\" outputclass=\"int-heading-drug\">Rosuvastatin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"warfarin\" outputclass=\"int-drug\">warfarin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor INR and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rosuvastatin   increases   the anticoagulant effect of   warfarin .  Manufacturer advises monitor INR and adjust dose .    \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				}
			],
			"hasSearchLabel": " Rosuvastatin  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/rosuvastatin-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Rosuvastatin </title>"
			},
			"rdfs:label": "rosuvastatin"
		}
	]
}